DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/2czp9f/companion_diagnost) has announced the addition of the "Companion Diagnostics and Personalized Medicine Market Report 2012" report to their offering.

This is the latest and most up-to-date Market Report from Select Biosciences addressing the companion diagnostics (CDx) and personalized medicine marketplace. Personalized medicine is a broad field with several stakeholders all of which must be aligned in order to capture the immense potential value in targeting therapeutics to the correct patient populationthe field of stratified medicine.

Companion Diagnostics has been rapidly expanding over the past 3 years and in this market report we describe the current state of the marketplace from the following perspectives:

- All the Prognostic and Predictive Biomarkers with Potential Clinical Utility are describeda few have already been developed into CDx and we expect growth in this space

- Targeted Therapeutics, Associated Biomarkers, Therapeutic Indications, and Testing Mandates are Described

- Companion Diagnostics Partnerships and Collaborations from 2009 to 2012 are PresentedProvides an Up-to-Date State of the Industry Describing the Disease Areas being Addressed and Types of Biomarkers Being Deployed

- Quantitative Market Metrics

Quantitative Market Forecast: Market Sizing and Growth Rate

Revenue Breakout: Rx versus Dx

The rest is here:
Research and Markets: Companion Diagnostics and Personalized Medicine Market Report 2012

Comments are closed.